Medidata Selected by Worldwide Clinical Trials to Accelerate Trials and Transform Patient Experience

Leading global CRO adopts Medidata AI for better-informed trial planning

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an expansion of its relationship with Worldwide Clinical Trials (“Worldwide”), a full-service global contract research organization (CRO). The agreement will facilitate data-driven decision-making across Worldwide’s entire clinical operations with the implementation of Medidata AI and enable Worldwide to support customers by reducing trial timelines and improving site selection.

This new collaboration will catapult Worldwide into the next phase of its data evolution, powered by Medidata’s artificial intelligence solutions and its expansive historical data set, the largest in the industry.

“Worldwide will accelerate clinical research and advance the life sciences industry by leveraging site-level granularity and real-time actionable observations provided by Medidata AI’s turnkey solution,” says Tom Doyle, chief technology officer, Medidata.

"For over 10 years, we’ve partnered with Medidata to help our customers gather advanced, data-driven insights so they can make confident and well-informed decisions about the future direction of their clinical trials,” says Peter Benton, president and CEO, Worldwide Clinical Trials. “Incorporating Medidata AI Intelligent Trials into our studies will allow us to more systematically plan, design, and execute research so we can deliver a better experience for patients and sponsors.”

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508504595/en/